Z A Sayiner1, B Okyar2, B Kısacık3, E Akarsu1, M Özkaya2, M Araz1. 1. Gaziantep University School of Medicine, Dept. of Endocrinology and Metabolism, Gaziantep, Turkey. 2. Gaziantep University School of Medicine, Dept. of Internal Medicine, Gaziantep, Turkey. 3. Gaziantep University School of Medicine, Medical Park Gaziantep Hospital, Department of Rheumatology, Gaziantep, Turkey.
Abstract
AIMS: In August 2015, FDA published a black box declaring that DPP-4 inhibitors may cause severe joint pains. The impact on autoimmunity marker positivity of these drugs has not been comprehensively evaluated. We compared the incidence of arthritis/arthralgia in patients with T2DM who were using DPP-4 inhibitors and patients who were not using. METHODS: A number of 93 DPP-4 inhibitor users and 107 non-users were included into the study. Arthritis/arthralgia were found in 41 of 93 (44.1%) DPP-4 inhibitor users and in 19 of 107 (17.8%) non-users (p<0.05). RESULTS: No inflammatory rheumatological condition was identified in 27 of 41 (65.9%) patients in DPP-4 inhibitor user group as well as in 13 of 19 (68.4%) patients in non-user group (p>0.05). After adjusting for gender the incidence for arthritis/arthralgia was significantly increased in the DPP-4 inhibitor user group (p value for any DPP-inhibitor <0.05). There was 3.77 times increased risk for arthritis/arthralgia in the DPP-4 inhibitor using group (p value= 0.001) and this risk increases 2.43 times for each year of DPP-4 inhibitor usage. CONCLUSIONS: Arthritis/arthralgia were more common among T2DM patients who were using DPP-4 inhibitors compared to non-users, but the seropositivity did not differ between DPP-4 inhibitor users and non-users.
AIMS: In August 2015, FDA published a black box declaring that DPP-4 inhibitors may cause severe joint pains. The impact on autoimmunity marker positivity of these drugs has not been comprehensively evaluated. We compared the incidence of arthritis/arthralgia in patients with T2DM who were using DPP-4 inhibitors and patients who were not using. METHODS: A number of 93 DPP-4 inhibitor users and 107 non-users were included into the study. Arthritis/arthralgia were found in 41 of 93 (44.1%) DPP-4 inhibitor users and in 19 of 107 (17.8%) non-users (p<0.05). RESULTS: No inflammatory rheumatological condition was identified in 27 of 41 (65.9%) patients in DPP-4 inhibitor user group as well as in 13 of 19 (68.4%) patients in non-user group (p>0.05). After adjusting for gender the incidence for arthritis/arthralgia was significantly increased in the DPP-4 inhibitor user group (p value for any DPP-inhibitor <0.05). There was 3.77 times increased risk for arthritis/arthralgia in the DPP-4 inhibitor using group (p value= 0.001) and this risk increases 2.43 times for each year of DPP-4 inhibitor usage. CONCLUSIONS: Arthritis/arthralgia were more common among T2DM patients who were using DPP-4 inhibitors compared to non-users, but the seropositivity did not differ between DPP-4 inhibitor users and non-users.
Entities:
Keywords:
DPP-4 inhibitors; Type 2 Diabetes Mellitus; arthralgia/arthritis
Authors: Caroline Ospelt; Joachim C Mertens; Astrid Jüngel; Fabia Brentano; Hanna Maciejewska-Rodriguez; Lars C Huber; Hossein Hemmatazad; Thomas Wüest; Alexander Knuth; Renate E Gay; Beat A Michel; Steffen Gay; Christoph Renner; Stefan Bauer Journal: Arthritis Rheum Date: 2010-05
Authors: Debora Williams-Herman; Samuel S Engel; Elizabeth Round; Jeremy Johnson; Gregory T Golm; Hua Guo; Bret J Musser; Michael J Davies; Keith D Kaufman; Barry J Goldstein Journal: BMC Endocr Disord Date: 2010-04-22 Impact factor: 2.763